RT Journal Article
SR Electronic
T1 A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.24.20134288
DO 10.1101/2020.06.24.20134288
A1 Hashimoto, Shoji
A1 Kitajima, Heita
A1 Arai, Tsuyoshi
A1 Tamura, Yoshitaka
A1 Nagai, Takayuki
A1 Morishita, Hiroshi
A1 Matsuoka, Hiroto
A1 Han, Yuki
A1 Minamoto, Seijiro
A1 Hirashima, Tomonori
A1 Yamada, Tomoki
A1 Kashiwa, Yozo
A1 Kameda, Makoto
A1 Yamaguchi, Seiji
A1 Uno, Kazuko
A1 Nakayama, Emi
A1 Shioda, Tatsuo
A1 Yoshizaki, Kazuyuki
A1 Kang, Sujin
A1 Kishimoto, Tadamitsu
A1 Tanaka, Toshio
YR 2020
UL http://medrxiv.org/content/early/2020/06/30/2020.06.24.20134288.abstract
AB We administered tocilizumab into 13 severe-to-critically ill patients with coronavirus disease 2019 (COVID-19) for compassionate use in combination with potential anti-viral agents in those who required an oxygen supply and showed increased laboratory inflammatory markers such as C-reactive protein (CRP) and ferritin. One injection of tocilizumab led to rapid improvements in clinical features, inflammatory findings, and oxygen supply in seven patients with severe COVID-19 and substantial amelioration in two patients who were critically ill, whereas four patients, who exhibited rapidly worsened respiratory function, required artificial ventilatory support even after tocilizumab treatment. Three of these four patients ultimately recovered from deterioration after methylprednisolone treatment. Administration of tocilizumab did not affect viral elimination nor IgG production specific for the virus. Compared with well-responding patients, rapidly-worsened patients showed a significantly higher ratio of ferritin vs. CRP. These findings suggest that tocilizumab has beneficial effects in severe-to-critically ill patients with COVID-19; however, in some cases, addition of methylprednisolone is required for disease rescue.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis manuscript reports findings of observational research of compassionate use of tocilizumab.Funding StatementNo funding was received for this report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of Osaka Habikino Medical Center (Approved ID: 150-7).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of all data were included in the manuscript.